



**Thursday, October 15, 2015**  
**7:00 a.m. to 8:30 a.m.**  
**Cannon Health Building**  
**Room 128**

**Committee Members Present:**

Bryan Larson, PharmD  
Clinton Sheffield, MD  
Ellie Brownstein, MD

Beth Young, PharmD  
Keith Tolman, MD

**Committee Members Excused:**

Beth Johnson, RPh

Jameson Rice, PharmD

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Robyn Seely, PharmD  
Heather Santacruz, RN

Chad Hope, PharmD

**University of Utah Drug Regimen Review Center Staff Present:**

Melissa Archer, PharmD

**Other Individuals Present:**

John Sandstrom, Baxalta  
John Cheppo, Grifols  
Paul Bonham, Novo  
Lynsey Spence, State Auditor's office

Gary Oderda, UofU  
Greg Hadlock, UofU  
Greg Gittus, Alkermes  
Cody Ball, Select Health

Meeting conducted by: Clinton Sheffield, MD

---

1. **Welcome & Housekeeping:** Clinton Sheffield welcomed everyone to the meeting.
2. **Review and Approval of August Minutes:** Keith Tolman made a motion to approve the minutes from September. Clinton Sheffield seconded the motion. All in favor.
3. **Drug Utilization Review (DUR) Board update:** The DUR board reviewed PCSK-9 agents: Praluent (alirocumab) and Repatha (evolocumab) at the last meeting. No action was taken and the topic will be carried forward to the next meeting.
4. **Immune Globulin Agents:** Melissa Archer presented a review of the Immune Globulin agents. She presented peer-reviewed research regarding the efficacy of the agents and discussed safety issues along with why there is very little comparative data on safety. She

discussed clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

5. **Public Comment:** John Sandstrom, (Baxalta) – He briefly discussed information about Hyqvia and offered to answer any questions the committee might have.
6. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States Medicaid programs.
7. **Board Discussion**
  - a. The committee discussed issues relevant to the use of Immune Globulin agents, particularly as they relate to the P&T Committee and the Utah Medicaid preferred Drug List.
  - b. NOTE: the audio recording for this meeting failed, so the minutes are abbreviated from what they would normally be.
  - c. Ellie Brownstein made a motion to add the Immune Globulin agents to the PDL as equally safe and efficacious for their approved indications with a requirement that at least one agent be preferred for each condition for which there is an FDA approved indication for Immune Globulin and that there should be one low IgA product preferred. Beth Young seconded the motion. All in favor.
8. **Meeting Adjourned**
9. Next meeting is scheduled for November 19, 2015. Ophthalmic Beta-Adrenergic Agonists and Ophthalmic Cholinergic agents will be discussed.

---

Minutes prepared by Trevor Smith

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)